The COVID-19 Pandemic and Cancer Screening Deficits in the United States
A retrospective cohort study quantified cancer screening deficits in the U.S. associated with the COVID-19 pandemic and identified differences according to region and socioeconomic status...
Oncologists’ Views on Challenges in Opioid Prescribing for Patients With Cancer-Related Pain
An interview study identified challenges and measures for improvement cited by oncologists in the safe and effective prescribing of opioids for their patients with cancer-related pain...
Diagnosis-to-Treatment Interval and Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
A study found that a short diagnosis-to-treatment interval in patients with DLBCL was associated with higher baseline tumor burden, reflected in higher pretreatment ctDNA levels...
Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer
There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Jame Abraham: Breast Cancer Screening With Clinical Breast Examination in Low- and Middle-Income Countries
Matthew Zibelman: Pembrolizumab in First-Line Treatment of Metastatic Clear Cell and Non–Clear Cell RCC
Nancy E. Davidson on Cancer and COVID-19: Reflections at 1 Year
Nadine M. Tung on Breast Cancer Susceptibility Genes: Putting the Pieces Together
Chandrakanth Are on the Physician-Patient Relationship
Sponsored Content
Sponsored by Puma Biotechnology
Adjuvant Therapy in HER2-Positive, Hormone Receptor–Positive Breast Cancer
AI System May Aid in Diagnosing Cancer of Unknown Primary
In 1% to 2% of cancer cases, the primary site of tumor origin cannot be determined. Because many modern cancer therapeutics target primary tumors, the prognosis for a cancer of unknown primary (CUP) is poor, with a median overall survival of 2.7 to 16 months. In order to receive a more specific...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Lobaplatin- vs Cisplatin-Based Induction and Chemoradiotherapy in Previously Untreated Locoregionally Advanced Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Lv et al found noninferior progression-free survival with induction therapy with the third-generation platinum lobaplatin/fluorouracil vs cisplatin/fluorouracil, followed by lobaplatin- vs cisplatin-based chemoradiotherapy, in patients...
One vs Two Doses of the BNT162b2 COVID-19 Vaccine in Patients With Cancer: Immunogenicity and Efficacy
In an interim analysis of a prospective observational study reported in The Lancet Oncology, Monin et al found that a single dose of the BNT162b2 Pfizer–BioNTech COVID-19 vaccine was poorly immunogenic in patients with cancer, with immunogenicity markedly improving at 2 weeks after a second dose...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Early-Stage Unfavorable-Risk Hodgkin Lymphoma
In a pilot study reported in the Journal of Clinical Oncology, Kumar et al found that the combination of brentuximab vedotin with AVD (doxorubicin, vinblastine, and dacarbazine) was highly active in patients with newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma and may permit the...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
